AxoGen - AXGN Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AXGN shares.
View AXGN analyst ratings or view top-rated stocks.

4 Wall Street analysts have issued 12-month price targets for AxoGen's shares. Their AXGN share price forecasts range from $15.00 to $20.00. On average, they expect the company's stock price to reach $16.67 in the next twelve months. This suggests a possible upside of 51.2% from the stock's current price.
View analysts price targets for AXGN or view top-rated stocks among Wall Street analysts.

AxoGen's stock was trading at $9.37 at the start of the year. Since then, AXGN shares have increased by 17.6% and is now trading at $11.02.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our AXGN earnings forecast.

AxoGen, Inc. (NASDAQ:AXGN) posted its earnings results on Wednesday, August, 3rd. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.09. AxoGen had a negative trailing twelve-month return on equity of 23.18% and a negative net margin of 24.68%. During the same period in the previous year, the business posted ($0.18) EPS.

AxoGen issued an update on its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $135.00 million-$142.00 million, compared to the consensus revenue estimate of $139.34 million.

19 employees have rated AxoGen Chief Executive Officer Karen Zaderej on Glassdoor.com. Karen Zaderej has an approval rating of 100% among the company's employees. This puts Karen Zaderej in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at AxoGen to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Advanced Micro Devices (AMD), Bank of America (BAC), Intelsat (I), Intel (INTC), Micron Technology (MU), Xilinx (XLNX), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), NVIDIA (NVDA) and Fossil Group (FOSL).

AxoGen trades on the NASDAQ under the ticker symbol "AXGN."

AxoGen's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include First Light Asset Management LLC (7.15%), Point72 Asset Management L.P. (4.93%), William Blair Investment Management LLC (3.90%), State Street Corp (2.18%), Millennium Management LLC (1.28%) and Assenagon Asset Management S.A. (1.23%). Insiders that own company stock include Angelo Scopelianos, Erick Wayne Devinney, Gregory Gene Freitag, Isabelle Billet, Karen L Zaderej, Karen L Zaderej, Maria D Martinez, Michael Patrick Donovan and Peter J Mariani.
View institutional ownership trends.

Shares of AXGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AXGN stock can currently be purchased for approximately $11.02.

AxoGen (NASDAQ:AXGN) has a market capitalization of $465.97 million and generates $127.36 million in revenue each year. The medical equipment provider earns $-26,990,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis.

The company employs 428 workers across the globe.

AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The official website for the company is www.axogeninc.com. The medical equipment provider can be reached via phone at (386) 462-6800, via email at investorrelations@axogeninc.com, or via fax at 386-462-6801.